Compare QNCX & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QNCX | IRIX |
|---|---|---|
| Founded | 2012 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 15.0M |
| IPO Year | 2019 | 1996 |
| Metric | QNCX | IRIX |
|---|---|---|
| Price | $33.75 | $0.71 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.5K | ★ 95.1K |
| Earning Date | 04-10-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,593,000.00 |
| Revenue This Year | N/A | $3.07 |
| Revenue Next Year | N/A | $6.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.08 | $0.70 |
| 52 Week High | $35.41 | $1.65 |
| Indicator | QNCX | IRIX |
|---|---|---|
| Relative Strength Index (RSI) | 61.57 | 30.29 |
| Support Level | $0.82 | N/A |
| Resistance Level | $35.41 | $1.16 |
| Average True Range (ATR) | 2.46 | 0.05 |
| MACD | -0.79 | -0.01 |
| Stochastic Oscillator | 34.79 | 4.14 |
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.